| Name | Title | Contact Details |
|---|
The mission of Crescendo Bioscience, Inc. is to enable more effective management of autoimmune and inflammatory diseases by providing quantitative, objective molecular tests and disease information services to rheumatologists and patients. Crescendo Bioscience is currently focused on rheumatoid arthritis (RA), a debilitating, chronic disease affecting over 1.5 million people in the United States and more than 2 million in Europe. Although there is no known cure for RA, multiple therapies are available, with widely differing levels of effectiveness and significant potential toxicities. Choosing the optimal treatment from among these therapeutic alternatives is a tremendous challenge. At Crescendo Bioscience, we are committed to improving rheumatologists’ ability to understand the biology underlying RA and to better determine the status of a patient’s disease. Vectra® DA is the first and only multi-biomarker blood test validated to measure RA disease activity. Vectra DA integrates the concentrations of 12 serum proteins associated with RA disease activity into a single objective score to help physicians make more informed treatment decisions. Crescendo Bioscience has also developed MyRA™, a free mobile app for people living with RA which was designed to empower patients to regularly track multiple aspects (e.g. medications, morning stiffness, joint pain, daily functionality, etc.) of their RA and easily share the information with their physician.
Inland Imaging is a Gilbert, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Phase 1 Molecular Toxicology (2720-99) is a Santa Fe, NM-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Buffalo MRI is a Buffalo, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PRACS Institute is a Fargo, ND-based company in the Healthcare, Pharmaceuticals, and Biotech sector.